Intestinal apoM inhibition as a specific approach to reduce plasma chylomicron and triglyceride levels

This technology reduces blood triglyceride and chylomicron levels by specifically inhibiting apolipoprotein M in the intestine, offering a new way to lower cardiovascular risk and treat lipid disorders not addressed by current therapies.

Background:

Cardiovascular disease remains a leading cause of morbidity and mortality worldwide, with dyslipidemia—abnormal levels of lipids in the blood—being a major risk factor. A key component of postprandial (after eating) lipid metabolism is the formation of chylomicrons in the small intestine, which transport dietary fats through the bloodstream. Elevated levels of chylomicrons and their remnants are strongly associated with the development of atherosclerosis, as these particles are particularly rich in cholesterol and can promote plaque formation in arterial walls. Despite advances in lipid-lowering therapies, such as statins and PCSK9 inhibitors, there is a persistent need for new strategies that specifically address the postprandial surge in triglyceride-rich lipoproteins, which are inadequately targeted by current treatments. Existing therapeutic approaches primarily focus on lowering low-density lipoprotein (LDL) cholesterol or total plasma triglyceride levels through systemic mechanisms, but they do not selectively inhibit chylomicron production in the intestine. As a result, patients with metabolic syndrome, insulin resistance, or genetic predispositions to hypertriglyceridemia often continue to experience elevated postprandial lipid levels and residual cardiovascular risk. Furthermore, chylomicron remnants are even more atherogenic than LDL particles due to their higher cholesterol content, yet no approved therapy directly targets their intestinal synthesis. This gap in treatment options highlights a critical unmet need for interventions that can specifically disrupt the formation of chylomicrons at their source, thereby offering more effective management of atherogenic dyslipidemia and its complications.

Technology Overview:

This technology introduces a targeted approach to reducing plasma chylomicron and triglyceride levels by inhibiting apolipoprotein M (apoM) in the intestine. Chylomicrons are lipoproteins produced in the small intestine from dietary fats and are significant contributors to dyslipidemia, insulin resistance, and atherosclerosis due to their high cholesterol content. By targeting apoM expression or function in intestinal tissues, this approach reduces chylomicron formation, thereby lowering plasma triglyceride concentrations. The technology is designed to be anti-atherogenic and anti-atherosclerotic, directly addressing a critical pathway in lipid metabolism that current therapies do not specifically target. What differentiates this technology is its unique specificity for intestinal apoM, rather than systemic inhibition or broader lipid-lowering mechanisms. Existing therapies do not directly target chylomicron production in the intestine, leaving a significant gap in the management of postprandial lipid spikes and their associated cardiovascular risks. By intervening at the source of chylomicron formation, this solution offers a novel strategy to reduce the levels of the most atherogenic lipoprotein particles in circulation. This targeted approach holds promise for developing new drugs, biologics, or gene therapies to treat cardiovascular disease, metabolic syndrome, and related lipid disorders, representing a significant advancement over current lipid management options.

Advantages:

•    Specifically reduces intestinal apolipoprotein M (apoM) to lower chylomicron production
•    Effectively decreases plasma triglyceride levels
•    Provides a novel anti-atherogenic and anti-atherosclerotic therapeutic approach
•    Targets chylomicron formation, a mechanism not addressed by current lipid-lowering therapies
•    Potentially beneficial for treating cardiovascular disease, metabolic syndrome, and lipid disorders
•    Enables use of diverse inhibition methods, including genetic, pharmacological, and molecular strategies
•    Minimizes systemic side effects by focusing inhibition specifically within the intestine

Applications:

•    Cardiovascular disease therapeutics
•    Metabolic syndrome treatment
•    Lipid-lowering drug development
•    Anti-atherosclerosis biologics

Intellectual Property Summary: Patent pending

Stage of Development: TRL 3: This technology is at an early preclinical development stage with proof‑of‑concept demonstrated through experimental suppression of intestinal apoM and corresponding reductions in chylomicron and triglyceride formation in relevant in vitro and in vivo models.

Licensing Status: This technology is available for licensing.

About the Research Foundation for the State University of New York:

As the nation's largest research foundation supporting the nation's largest public university system, The Research Foundation for SUNY powers research and innovation to address today's most pressing problems and shape a better future for generations to come. The Research Foundations supports SUNY researchers leading the way globally in AI for the public good, quantum technologies, next-generation semiconductors, biotech and medicine, energy and climate solutions, and more. The Research Foundation for SUNY is a private, nonprofit educational corporation that is tax-exempt under Internal Revenue Code (IRC) Section 501(c)(3). To learn more, please visit us online at rfsuny.org.

About the State University of New York

The State University of New York is the largest comprehensive system of higher education in the United States, and more than 95 percent of all New Yorkers live within 30 miles of any one of SUNY’s 64 colleges and universities. Across the system, SUNY has four academic health centers, five hospitals, four medical schools, two dental schools, a law school, the country’s oldest school of maritime, the state's only college of optometry, 12 Educational Opportunity Centers, over 30 ATTAIN digital literacy labs, and manages one US Department of Energy National Laboratory. In total, SUNY serves about 1.7 million students across its portfolio of credit- and non-credit-bearing courses and programs, continuing education, and community outreach programs. SUNY oversees nearly a quarter of academic research in New York. Research expenditures system-wide are nearly $1.5 billion in fiscal year 2025, including significant contributions from students and faculty. There are more than three million SUNY alumni worldwide, and annually one in three New Yorkers who earn a college degree is a SUNY alum. To learn more about how SUNY creates opportunities, visit suny.edu.